Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid

British Journal of Clinical Pharmacology

Volumn 69, Issue 2, 2010, Pages 167-178

  Landersdorfer, Cornelia B ^a,h   Kirkpatrick, Carl M J ^b   Kinzig, Martina ^a   Bulitta, Jürgen B ^a,h   Holzgrabe, Ulrike ^c   Jaehde, Ulrich ^d   Reiter, Andreas ^e   Naber, Kurt G ^f   Rodamer, Michael ^a   Sörgel, Fritz ^a,g  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

^h ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

Ciprofloxacin; Competitive inhibition; Metabolite formation; Modelling of pharmacokinetic interaction; Probenecid

Indexed keywords

2 AMINOETHYLAMINO; CIPROFLOXACIN; DRUG METABOLITE; PROBENECID; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; ANALYSIS OF VARIANCE; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; KIDNEY TUBULE; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; STATISTICS;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; KIDNEY TUBULES; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PROBENECID; STATISTICS AS TOPIC;

EID: 75149118366     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03564.x     Document Type: Article

References (32)

1. Eliopoulos GM, Gardella A, Moellering RC Jr. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother 1984 25 : 331 335.
2. Ullrich KJ, Rumrich G, David C, Fritzsch G. Bisubstrates: substances that interact with both, renal contraluminal organic anion and organic cation transport systems. II. Zwitterionic substrates: dipeptides, cephalosporins, quinolone-carboxylate gyrase inhibitors and phosphamide thiazine carboxylates; nonionizable substrates: steroid hormones and cyclophosphamides. Pflugers Arch 1993 425 : 300 312.
3. Kamali F. The effect of probenecid on paracetamol metabolism and pharmacokinetics. Eur J Clin Pharmacol 1993 45 : 551 553.
4. Kamali F, Rawlins MD. Influence of probenecid and paracetamol (acetaminophen) on zidovudine glucuronidation in human liver in vitro. Biopharm Drug Dispos 1992 13 : 403 409.
5. Gisclon LG, Boyd RA, Williams RL, Giacomini KM. The effect of probenecid on the renal elimination of cimetidine. Clin Pharmacol Ther 1989 45 : 444 452.
6. Nakashima M, Uematsu T, Kosuge K, Kusajima H, Ooie T, Masuda Y, Ishida R, Uchida H. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995 39 : 2635 2640.
7. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997 32 : 101 119.
8. Gaitonde M, Mendes P, House ESA, Lehr KH. The Effects of Cimetidine and Probenecid on the Pharmacokinetics of Levofloxacin. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995.
9. Shimada J, Yamaji T, Ueda Y, Uchida H, Kusajima H, Irikura T. Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrob Agents Chemother 1983 23 : 1 7.
10. Shiba K, Saito A, Shimada J, Hori S, Kaji M, Miyahara T, Kusajima H, Kaneko S, Saito S, Ooie T, Uchida T. Renal handling of fleroxacin in rabbits, dogs, and humans. Antimicrob Agents Chemother 1990 34 : 58 64.
11. Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. J Antimicrob Chemother 1988 21 (Suppl. B 67 77.
12. Stass H, Sachse R. Effect of probenecid on the kinetics of a single oral 400 mg dose of moxifloxacin in healthy male volunteers. Clin Pharmacokinet 2001 40 (Suppl. 1 71 6.
13. Shimada J, Nogita T, Ishibashi Y. Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 1993 25 : 358 369.
14. Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin Pharmacol Ther 1995 58 : 532 541.
15. Landersdorfer C, Kirkpatrick CM, Kinzig-Schippers M, Bulitta J, Holzgrabe U, Sorgel F. New insights into the most commonly studied drug interaction with antibiotics: pharmacokinetic interaction between ciprofloxacin, gemifloxacin and probenecid at renal and non-renal sites. 15th Annual Meeting of the Population Approach Group in Europe (PAGE), Brugge, Belgium, 2006.
16. Emanuelsson BM, Beermann B, Paalzow LK. Non-linear elimination and protein binding of probenecid. Eur J Clin Pharmacol 1987 32 : 395 401.
17. Vree TB, Van Ewijk-Beneken Kolmer EW, Wuis EW, Hekster YA. Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. Pharm Weekbl Sci 1992 14 : 325 331.
18. Garton AM, Rennie RP, Gilpin J, Marrelli M, Shafran SD. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels. J Antimicrob Chemother 1997 40 : 903 906.
19. Vlasses PH, Holbrook AM, Schrogie JJ, Rogers JD, Ferguson RK, Abrams WB. Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. Antimicrob Agents Chemother 1980 17 : 847 855.
20. Masereeuw R, Russel FG. Mechanisms and clinical implications of renal drug excretion. Drug Metab Rev 2001 33 : 299 351.
21. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 1997 26 : 1667 1677.
22. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005 45 : 689 723.
23. Sorgel F, Bulitta J, Kinzig-Schippers M. How well do gyrase inhibitors work? The pharmacokinetics of quinolones. Pharm Unserer Zeit 2001 30 : 418 427.
24. Burckhardt BC, Brai S, Wallis S, Krick W, Wolff NA, Burckhardt G. Transport of cimetidine by flounder and human renal organic anion transporter 1. Am J Physiol Renal Physiol 2003 284 : F503 9.
25. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, Sugiyama Y. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 2005 315 : 337 345.
26. Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Giacomini KM. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol 2006 290 : F905 12.
27. Stein GE. Drug interactions with fluoroquinolones. Am J Med 1991 91 : 81S 86S.
28. Allen A, Bird N, Dixon R, Hickmott F, Pay V, Smith A, Stahl M. Effect of cimetidine on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Clin Drug Invest 2001 21 : 519 526. (Pubitemid 32681924)
29. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003 55 : 425 461.
30. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther 1999 290 : 672 677.
31. Vanwert AL, Srimaroeng C, Sweet DH. Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol 2008 74 : 122 131.
32. Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 2003 146 : 95 158.